The Comparison of Flot Vs. Mdcf Regimens in Neoadjuvant Setting for Locally-Advanced Gastric Cancer

Abstract

Objectives: To compare the pathological tumor response and survival of mDCF (modified docetaxel+cisplatin+5- flourosil) vs. FLOT (5-flourosil+oxaliplatin+dosataxel) regimens in the neoadjuvant setting for patients with locally- advanced gastric adenocarcinoma. Methods: A total of 72 patients, 44 males and 28 females, who were diagnosed with locally-advanced gastric adeno- carcinoma and treated with neoadjuvant chemotherapy were included. Postoperative pathological tumor response, disease free survival (DFS) and overall survival (OS) were compared between the two treatment groups (FLOT and mDCF group). Results: Median DFS was 19.0 months in the FLOT arm (long rank p=0.218), while median DFS could not be reached in the mDCF arm. Rate of DFS in 6, 12,18 and 24 months were 95,4%, 80,9%, 63% and 42% in FLOT group, respectively. In mDCF group, rate of DFS in 6, 12, 18 and 24 months were 100%, 88%, 71,2% and 62,2%, respectively. Median OS was not reached in both groups (long rank p=0.514). There was no significant difference between the treatment regimens (mDCF and FLOT) in terms of response to the treatment, DFS, and OS. Conclusion: Since no significant difference was observed between the regimens in terms of treatment response and survival, we think that cisplatin can be preferred instead of oxaliplatin as a part of neoadjuvant treatment regimen in elderly patients with diabetic neuropathy or high risk of neuropathy.